
Intensity Therapeutics Issued First US Patent for Immune-based Cancer Therapeutic Agents

- Patent 9,351,997 protects lead product INT230-6.

Westport, CT. – June 02, 2016 - [Intensity Therapeutics, Inc.](#), a privately held biotechnology company developing proprietary cancer immunotherapy products, today announced that the United States Patent and Trademark Office issued the Company US Patent 9,351,997.

“Intensity’s DfuseRxSM platform technology has identified our lead drug, INT230-6. This novel product has shown great promise in regressing tumors and extending life in murine models of severe metastatic cancer via a combination of tumor cell death and immune system activation. Animals with large tumors achieve a complete response and become immunized against re-inoculation of the same cancer,” said [Intensity’s President and CEO, Lewis H Bender](#). “This issued US patent allows us to protect the market exclusivity of our unique and potent drug product. As we continue to prosecute additional patent applications in the US and countries around the world, the issuance of patent 9,351,997 increases our confidence that the Company’s unique cancer treatment technology can be secured.”

About INT230-6

INT230-6 is a novel, anti-cancer drug product able to disperse through tumors and diffuse into cancer cells. The product was identified from Intensity’s DfuseRxSM platform technology. Using preclinical *in vivo* models of severe cancer, INT230-6 treatment results in substantial improvement in overall survival compared to standard therapies. The product can completely clear large tumors in animal models. Complete responders have long-term, durable protection even after multiple re-inoculations of the cancer. INT230-6 administration has shown an increased recruitment of immune cells to the tumor micro-environment.

About Intensity Therapeutics, Inc.

Intensity Therapeutics, Inc. is a biotechnology company whose mission is to greatly extend the lives of patients with cancer. Intensity Therapeutics is pioneering a new immune-based approach to treat cancer - *in situ* vaccination. The Company uses its DfuseRxSM platform technology to create new products capable of attenuating (killing) a tumor in a manner that allows for the adaptive immune system to recognize the cancer and attack tumors. Further information can be found at www.intensitytherapeutics.com

Forward-Looking Statements

This press release contains forward-looking statements regarding Intensity Therapeutics' plans, future operations and objectives. Such statements involve known and unknown risks, uncertainties and other factors that may cause actual performance or achievements to be materially different from those currently anticipated. These forward-looking statements include, among other things, statements about the initiation and timing of future clinical trials.

Contacts:Investors:

Lewis Bender
President & CEO
8 Wright Street, Suite 107
Westport, CT 06880
Tel. (203) 682-2434
Email: lbender@intensitytherapeutics.com

Media

Aline Sherwood
Scienta Communications
Tel: (312) 238-8957
Email: asherwood@scientapr.com